Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Appoints Assistant Commissioner For Science Ahead Of Plan B Decision

This article was originally published in The Pink Sheet Daily

Executive Summary

Former Center for Veterinary Medicine Deputy Director Linda Tollefson will oversee FDA's Offices of Women's Health and Orphan Products Development.

You may also be interested in...



FDA Women’s Health Director Resigns Over Plan B

Susan Wood says she can “no longer serve as staff when scientific and clinical evidence...has been overruled.”

FDA Women’s Health Director Resigns Over Plan B

Susan Wood says she can “no longer serve as staff when scientific and clinical evidence...has been overruled.”

Correction: FDA Office Of Women’s Health

The first major undertaking for new FDA Assistant Commissioner for Science Linda Tollefson under her duties as head of FDA's Office of Women's Health is likely to be responding to the agency's decision on the over-the-counter switch application for Barr's Plan B contraceptive

Topics

UsernamePublicRestriction

Register

OM006051

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel